On March 29th, Gelon Exchange (1302.HK) rose 4.87% to HK $2.80, with a total market capitalization of HK $12.9 billion. The company announced yesterday that the innovative iron-based absorbable stent system ("IBS Angel stent"), independently developed by Yuanxin Technology (Shenzhen) Co., Ltd., a subsidiary of Xianjian Technology Holdings, has successfully completed its first implantation in the United States at Wisconsin Children's Hospital in West Ellis, USA. This product has been approved by FDA "Compassionate Use" (compassionate use) and is the second product successfully implanted in the United States under the iron-based absorbable material platform of Sijian Technology.